Science to Market - S2M

New rules for diagnostic products, but who will certify them? “An extreme shortage area”

In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and...

Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Lösning hittad för Orexos patenttvist

En långdragen patenttvist mellan Uppsalabolaget Orexo och indiska Sun Pharmaceutical Industries är nu löst genom förlikning.

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward...

SGS Fimko Ltd.

Mercodia AB

Conference on Alzheimer’s reveals several advances in the field

In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Sci...

Thomas Eldered: ”Innovation is the key”

Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.

Källor: CDC planerar studie av vacciner och autism

Samtidigt som USA har sitt största mässlingsutbrott på decennier planerar landets smittskyddsmyndighet en studie om koppling mellan autism och vaccin, enligt kä...

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...

NorthX Biologics Matfors AB

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

This is how Anette Steenberg will put Medicon Valley on the world map

Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to a...

A modular system for precise and automated cell dispensing

How the benefits of laboratory automation can be combined with gentle cell handling.

The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...

Ovanlig genetisk sjukdom behandlad i livmodern för första gången

Ett barn har för första gången behandlats mot spinal muskelatrofi redan i magen på sin mamma. Barnet, som nu är två och ett halvt år gammalt, visar inga symptom...

Save time and money !

Festo Digital engineering tools helps you to calculate the most cost and efficient solution for your application for free

Bolag anklagas för att ha mörkat förhöjd risk för deltagare i alzheimerstudier

Ett stort antal deltagare i de kliniska alzheimerstudierna av lecanemab och donanemab bar på en genvariant som gjorde att de löpte förhöjd risk för allvarliga b...

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new...